Onychomycosis is a fungal nail infection caused by dermatophytes, nondermatophytes, and yeast, and is the most common nail disorder seen in clinical practice. It is an important problem because it may cause local pain, paresthesias, difficulties performing activities of daily living, and impair social interactions. The epidemiology, risk factors, and clinical presentation and diagnosis of onychomycosis were discussed in the first article in this continuing medical education series. In this article, we review the prognosis and response to onychomycosis treatment, medications for onychomycosis that have been approved by the US Food and Drug Administration, and off-label therapies and devices. Methods to prevent onychomycosis recurrences and emerging therapies are also described.Le texte complet de cet article est disponible en PDF.
Key words : booster therapy, ciclopirox, clinical cure, complete cure, efinaconazole, fluconazole, fungal nail infection, itraconazole, lasers, mycologic cure, onychomycosis, photodynamic therapy, plasma therapy, pulse dosing, tavaborole, terbinafine, treatment
Abbreviations used : ALA, DLSO, FDA, NDM, PDT
| Date of release: April 2019
| Expiration date: April 2022
| Funding sources: None.
| Dr Scher has received honoraria from MOE Medical Devices, Epihealth, Medicxi, and Valeant. Dr Lipner has received grants for clinical trials from MOE Medical Devices.
| Reprints not available from the authors.